by The global diabetes associated ophthalmic treatment market size is expected to be worth around US$ 50.7 billion by 2030, according to a new report by Vision Research Reports.
The global diabetes associated ophthalmic treatment market size was valued at US$ 28.2 billion in 2020 and is anticipated to grow at a CAGR of 7.5% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38804
Table of Contents
Diabetes Associated Ophthalmic Treatment Market Growth Factors
The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth. This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options. An increasing number of clinical trials to assess new drugs and devices for the prevention and management of these ophthalmic conditions are expected to fuel market growth in upcoming years.
An increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities.
Diabetes Associated Ophthalmic Treatment Market Report Coverage
| Report Scope | Details |
| Market Size | US$ 50.7 Bn by 2030 |
| Growth Rate | CAGR of 7.5% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, application; end-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Alcon; Johnson & Johnson Services, Inc.; Bausch Health; Allergan; Bayer AG; Santen Pharmaceutical Co. Ltd.; Novartis AG; Pfizer, Inc.; Genentech, Inc.; Carl Zeiss Meditec; Lumenis; Ellex Medical Lasers Ltd.; IRIDEX Corporation; Topcon Corporation; Abbott Medical Optics; Quantel |
By Type Analysis
The drugs segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of 58.6% in 2020. The drug segment comprises anti-glaucoma drugs, anti-inflammatory drugs, anti-VEGF drugs, anti-allergy drugs, and others.
The devices segment is growing at a rapid pace accounted for a CAGR of 6.4% during the forecast period. The devices segment comprises refractive error surgical devices, glaucoma surgical devices, cataract surgical devices, vitreoretinal surgical devices, diagnostic devices, and visual aid devices.
By End-use Analysis
The hospital segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of 39.4% in 2020. An increasing number of hospital admissions of diabetes patients are boosting the demand for the segment,
By Application Analysis
The diabetic retinopathy segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of around 26.0% in 2020. Diabetic retinopathy is considered a critical medical condition that impacts the eyes of the patient leading to vision loss.
increasing clinical trials for the approval of drugs used for the treatment of diabetic retinopathy is expected to boost the growth of the market for diabetes associated ophthalmic.
By Regional Analysis
North America dominated the diabetes associated ophthalmic treatment market and held the largest revenue share of 37.5% in 2020. The growth in the region is mainly attributed to factors such as robust healthcare infrastructure,
In Asia Pacific, the market for diabetes associated ophthalmic is expected to witness the fastest growth rate during the forecast period. The growing ophthalmic disorders burden and rising consumer awareness are expected to drive the market for diabetes associated ophthalmic in the region.
Read also @ Healthcare Cyber Security Market to Reach US$ 44.5 Bn by 2030
Major Key Players Covered in The Diabetes Associated Ophthalmic Treatment Market Report include
- Alcon
- Johnson & Johnson Services, Inc.
- Bausch Health
- F. Hoffmann-La Roche Ltd
- Allergan
- Bayer AG
- Santen Pharmaceutical Co. Ltd.
- Novartis AG
- Pfizer, Inc.
- Genentech, Inc.
- Carl Zeiss Meditec
- Lumenis
- Ellex Medical Lasers Ltd.
- IRIDEX Corp.
- Topcon Corp.
- Abbott Medical Optics
- Quantel
Diabetes Associated Ophthalmic Treatment Market Segmentation
- By Application
- Dry Eye Syndrome
- Glaucoma
- Eye Allergy & Infection
- Diabetic Retinopathy
- Diabetic associated Macular Degeneration
- Uveitis
- Cataract
- Diabetic Macular Edema
- Others
- By Type
- Drugs
- Devices
- By End-use
- Hospitals
- Ophthalmic Centers
- Ambulatory Surgical Centers
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Diabetes Associated Ophthalmic Treatment Market Snapshot
Chapter 4. Diabetes Associated Ophthalmic Treatment Market Variables and Scope
4.1. Introduction
4.2. Diabetes Associated Ophthalmic Treatment Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Application Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Diabetes Associated Ophthalmic Treatment Market Dynamics Analysis and Trends
5.1. Diabetes Associated Ophthalmic Treatment Market Dynamics
5.1.1. Diabetes Associated Ophthalmic Treatment Market Drivers
5.1.2. Diabetes Associated Ophthalmic Treatment Market Restraints
5.1.3. Diabetes Associated Ophthalmic Treatment Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Diabetes Associated Ophthalmic Treatment Market, By Type
7.1. Diabetes Associated Ophthalmic Treatment Market, by Type, 2021-2030
7.1.1. Drugs
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Devices
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Diabetes Associated Ophthalmic Treatment Market, By Application
8.1. Diabetes Associated Ophthalmic Treatment Market, by Application, 2021-2030
8.1.1. Dry Eye Syndrome
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Glaucoma
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Eye Allergy & Infection
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Diabetic Retinopathy
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Diabetic associated Macular Degeneration
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Uveitis
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Cataract
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Diabetic Macular Edema
8.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Diabetes Associated Ophthalmic Treatment Market, By End-use
9.1. Diabetes Associated Ophthalmic Treatment Market, by End-use, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ophthalmic Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Ambulatory Surgical Centers
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Diabetes Associated Ophthalmic Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. Market Revenue and Forecast, by End-use (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. Market Revenue and Forecast, by End-use (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. Market Revenue and Forecast, by End-use (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. Market Revenue and Forecast, by End-use (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Market Revenue and Forecast, by End-use (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 11. Company Profiles
11.1. Raphas
11.1.1. Company Overview
11.1.2. Type Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Novartis International AG
11.2.1. Company Overview
11.2.2. Type Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Becton Dickinson and Company
11.3.1. Company Overview
11.3.2. Type Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. B. Braun
11.4.1. Company Overview
11.4.2. Type Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Nanopass Technologies Limited
11.5.1. Company Overview
11.5.2. Type Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Termo
11.6.1. Company Overview
11.6.2. Type Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Smiths Medical
11.7.1. Company Overview
11.7.2. Type Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cardinal Health
11.8.1. Company Overview
11.8.2. Type Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. 3M
11.9.1. Company Overview
11.9.2. Type Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38804
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
